#Ireland #Dublin #Nuritas #Kees Kruythoff #biotechnologie

Nuritas Appoints Kees Kruythoff as Chairman of the Board

Nuritas, a leading global biotechnology company specializing in the discovery of bioactive peptides, has officially announced the appointment of Kees Kruythoff as Chairman of the Board. This strategic decision marks a significant moment for Nuritas as it embarks on a mission to revolutionize everyday foods, making them healthier and more clinically validated. The vision is to usher in a new era where nutrition actively contributes to improved human health on a grand scale.

Kruythoff brings nearly 30 years of invaluable experience in international leadership gained during his tenure at Unilever. As a former executive committee member, he commanded operations with revenues ranging from €200 million to €12 billion. His distinguished career included remarkable roles such as the President of Unilever North America, President of the global Home Care division, and CEO of the company’s operations in Brazil and South Africa. His extensive experience spans Europe, Africa, Asia, Latin America, and the United States, providing him with deep insights into scaling innovation through international consumer brands and business partnerships.

Nuritas is at the forefront of providing clinically validated peptide ingredients integrated into leading consumer nutrition and wellness products globally. At the core of its innovation is the exclusive research platform Magnifier NπΦ, which analyzes natural and non-synthetic proteins to identify high-impact peptides that address critical health needs.

In Kees Kruythoff's words, "I believe Nuritas has a unique opportunity to positively impact the health and well-being of billions of people by combining natural ingredients with cutting-edge peptide research powered by AI. I am honored and excited to be part of this journey."

Dr. Nora Khaldi, the founder and CEO of Nuritas, states, "Kees brings a global vision, operational rigor, and a genuine passion for food transformation to our board. His expertise in market development and integrating health and sustainability into global consumer businesses makes him the ideal partner for Nuritas at this time. I am thrilled to welcome him to the team."

Collaboration is key as Kruythoff will work closely with Dr. Khaldi and the executive team, providing strategic guidance to strengthen international partnerships, expand the commercial reach of the peptide portfolio, and solidify Nuritas’ position at the intersection of AI, biotechnology, and human health.

About Nuritas

Nuritas leverages artificial intelligence to discover clinically validated natural peptides. Its exclusive Magnifier NπΦ platform allows for rapid analysis of proteins to identify peptides that can potentially enhance human health, enabling partners to bring scientifically grounded innovations to market faster. Founded in 2014 by mathematician and scientist Dr. Nora Khaldi, Nuritas is headquartered in Dublin, Ireland, with a North American base in Connecticut. Its partners include prominent names such as GNC, The Vitamin Shoppe, Mars, Nestlé, and Givaudan.